Marshall Wace North America’s Vanda Pharmaceuticals VNDA Stock Holding History

Marshall Wace North America’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-33,213	Closed	-$499K	–	1803
2021 Q1	$499K	Buy	+33,213	New	+$538K	﹤0.01%	1200
2020 Q3	–	Sell	-14,598	Closed	-$168K	–	1491
2020 Q2	$168K	Sell	14,598 -35,434	-71%	-$401K	﹤0.01%	1082
2020 Q1	$519K	Buy	50,032 +3,564	+8%	+$44.2K	﹤0.01%	748
2019 Q4	$763K	Sell	46,468 -33,000	-42%	-$499K	﹤0.01%	755
2019 Q3	$1.05M	Buy	+79,468	New	+$1.11M	0.01%	680
2013 Q4	$224K	Buy	+18,036	New	+$181K	﹤0.01%	628
2013 Q3	–	Sell	-11,856	Closed	-$96K	–	718
2013 Q2	$96K	Buy	+11,856	New	+$79.8K	0.01%	412

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

EIP

Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return

Marshall Wace North America's VNDA Position: Q2 2021 in Review

Marshall Wace North America sold out of Vanda Pharmaceuticals (VNDA) in Q2 2021, closing a stake of 33,213 shares — an estimated $499K sold.

Marshall Wace North America first reported a position in VNDA in Q2 2013 and held it in 7 quarters. The position peaked at $1.05M in Q3 2019. 181 funds tracked by Wall St. Rank hold VNDA as of Q2 2021.

Marshall Wace North America reported no remaining Vanda Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Marshall Wace North America sold 33,213 Vanda Pharmaceuticals shares in Q2 2021, an estimated $499K.
Marshall Wace North America first reported a position in Vanda Pharmaceuticals in Q2 2013 and held it in 7 quarters.
Marshall Wace North America's Vanda Pharmaceuticals position peaked at $1.05M in Q3 2019.
181 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2021.

Based on Marshall Wace North America's 13F filing for Q2 2021, filed 13 Aug 2021.